Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering
Erasca Inc (NASDAQ:ERAS) has entered into an exclusive worldwide license agreement with Novartis AG (NYSE:NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor…